Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42
2016 San Antonio Breast Cancer Symposium
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).
Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).
S.P. Somashekhar, MBBS, MCh(Onco), of the Manipal Comprehensive Cancer Centre, discusses a study to assess the performance of IBM's artificial intelligence platform in comparison to a multidisciplinary tumor board (Abstract S6-07).
Virginia G. Kaklamani, MD, DSc, of The University of Texas Health Science Center, discusses new directions in prevention, early detection, and treatment of early-stage breast cancer, using genomic tests and targeted therapies.
Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.
Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.